Cart
sales@molnova.com
RET-IN-1
CAS No. 2222755-14-6
RET-IN-1 ( —— )
Catalog No. M21830 CAS No. 2222755-14-6
RET-IN-1 is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 552, has IC50s of 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 1503 | Get Quote |
|
| 50MG | 3042 | Get Quote |
|
| 100MG | 4140 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameRET-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionRET-IN-1 is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 552, has IC50s of 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively .
-
DescriptionRET-IN-1 is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 552, has IC50s of 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively .
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2222755-14-6
-
Formula Weight553.255
-
Molecular FormulaC29H31N9O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN#CC1=C2C(C3=NC=C(N4CC(C5)N(CC6=CC=C(OC)N=C6)C5C4)N=C3)=CC(OC[C@H]7CNCCO7)=CN2N=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
4-Methoxysalicylic a...
2-hydroxy-4-methoxybenzoic acid is a predicted metabolite generated by BioTransformer1 that is produced by the metabolism of 3-(2-hydroxy-4-methoxyphenyl)propanoic acid.
-
Cynanoside F
Cynanoside F is a natural product for research related to life sciences.
-
Ecliptasaponin A
Ecliptasaponin A has protective effects against the pulmonary fibrosis induced by bleomycin via reducing the oxidative stress, lung tissue inflammation, and the subsequent epithelial-mesenchymal transition.
